Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Shuch

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
The American Journal of Surgical Pathology|April 29, 2026
International Society of Urological Pathology Consensus on Cancer Precursor Lesions: Working Group 3 Preneoplastic and Precursor Lesions of the KidneySean R Williamson, Sara E Wobker, Rohit Mehra, et al.
Lancet (London, England)|February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Lancet (London, England)|February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Targeted Oncology|September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 TrialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 20, 2025
The impact of the new WHO Classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinomaJan Degenhardt, Yuri Tolkach, Mahul B Amin, et al.
The Lancet. Oncology|September 13, 2024
[<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialBrian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.
International Journal of Cancer|November 15, 2012
An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studiesMark P Purdue, Lee E Moore, Maria J Merino, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Testicular Cancer, Version 2.2015Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
The American Journal of Surgical Pathology|April 29, 2026
International Society of Urological Pathology Consensus on Cancer Precursor Lesions: Working Group 3 Preneoplastic and Precursor Lesions of the KidneySean R Williamson, Sara E Wobker, Rohit Mehra, et al.
Lancet (London, England)|February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Lancet (London, England)|February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Targeted Oncology|September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 TrialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 20, 2025
The impact of the new WHO Classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinomaJan Degenhardt, Yuri Tolkach, Mahul B Amin, et al.
The Lancet. Oncology|September 13, 2024
[<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialBrian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.
International Journal of Cancer|November 15, 2012
An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studiesMark P Purdue, Lee E Moore, Maria J Merino, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Testicular Cancer, Version 2.2015Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Pageof 18